Catherine Geh

1.0k total citations
7 papers, 511 citations indexed

About

Catherine Geh is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Catherine Geh has authored 7 papers receiving a total of 511 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Catherine Geh's work include Cancer-related Molecular Pathways (3 papers), Cancer therapeutics and mechanisms (2 papers) and Biochemical and Molecular Research (2 papers). Catherine Geh is often cited by papers focused on Cancer-related Molecular Pathways (3 papers), Cancer therapeutics and mechanisms (2 papers) and Biochemical and Molecular Research (2 papers). Catherine Geh collaborates with scholars based in United Kingdom, South Korea and Taiwan. Catherine Geh's co-authors include Elizabeth A. Harrington, Claire Rooney, Michael Dymond, Roz Brant, Gayle Marshall, Hollie Emery, J. Carl Barrett, Alan Sharpe, Margaret H. Veldman-Jones and Chris Harbron and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Catherine Geh

7 papers receiving 504 citations

Peers

Catherine Geh

MB

ONCOL

PRM

CR

OC

Francis Bichat France

Jorg Michels Canada

Katie Kane United Kingdom

Rosario Garrido United States

Mary Luz Uribe Spain

Flora Luo United States

Sharon Glaysher United Kingdom

Robert D. Van Horn United States

Huihong You United States

Murray Yule United States

Francis Bichat France

Catherine Geh

273 ×1.2

MB

223 ×1.2

ONCOL

141 ×1.1

PRM

71 ×0.9

CR

41 ×0.6

OC

Citations per year, relative to Catherine Geh Catherine Geh (= 1×) peers Francis Bichat

Countries citing papers authored by Catherine Geh

Since Specialization

Citations

This map shows the geographic impact of Catherine Geh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Geh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Geh more than expected).

Fields of papers citing papers by Catherine Geh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Geh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Geh. The network helps show where Catherine Geh may publish in the future.

Co-authorship network of co-authors of Catherine Geh

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Geh. A scholar is included among the top collaborators of Catherine Geh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Geh. Catherine Geh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Rooney, Claire, Catherine Geh, Victoria Williams, et al.. (2016). Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon. PLoS ONE. 11(2). e0149628–e0149628. 21 indexed citations

2.

Veldman-Jones, Margaret H., Roz Brant, Claire Rooney, et al.. (2015). Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples. Cancer Research. 75(13). 2587–2593. 234 indexed citations

3.

Bang, Yung‐Jue, Eric Van Cutsem, Wasat Mansoor, et al.. (2015). A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study.. Journal of Clinical Oncology. 33(15_suppl). 4014–4014. 49 indexed citations

4.

Byth, Kate F., Andrew P. Thomas, Gareth Hughes, et al.. (2009). AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Molecular Cancer Therapeutics. 8(7). 1856–1866. 104 indexed citations

5.

Jones, Clifford D., David Andrews, Andrew Barker, et al.. (2008). Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(24). 6486–6489. 29 indexed citations

6.

Jones, Clifford D., David Andrews, Andrew Barker, et al.. (2008). The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing. Bioorganic & Medicinal Chemistry Letters. 18(24). 6369–6373. 33 indexed citations

7.

Byth, Kate F., et al.. (2006). The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor. Molecular Cancer Therapeutics. 5(3). 655–664. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact